Summary.-A serious limitation of chemotherapy for acute myeloid leukaemia (AML), Hodgkins disease and some classes of breast cancer is that, even when clinically evident disease responds well, the same chemotherapy when given during remission does not affect the rate of relapse after chemotherapeutic or surgical ablation of the primary disease. This cannot, in general, be caused by genetic adaptation of the residual cancer cells which renders them resistant to specific drugs, because after relapse further remissions can be obtained with the same drugs that were ineffective by chronic administration in prolonging remission. The resistance of the residual cells may arise from mechanisms such as inaccessibility for anatomical or other reasons, or because of a change in metabolic state which causes these cells temporarily to cease division, when they cannot be harmed by cycle-dependent drugs and repair damage sustained from cycle-independent drugs. Limited differentiation has been shown capable of reversal and this may be a mechanism which leads to quiescence and associated "resistance", particularly in the case of AML. Where such resistance occurs treatment during remission-or as an adjuvant to surgery and radiotherapy-may have to rely on mechanisms which are independent of cellular proliferation such as processes associated with graft-versus-host-disease or the induction of terminal differentiation. A model for studying the nature of resistance of residual cancer and for testing treatments that might be active against cancer cells in this state may be dormant metastases. The latter are malignant cells which appear to be in peaceful co-existence with their host and which in experimental systems have been induced to grow into lethal metastases by perturbation of the host by surgical trauma, by hormonal manipulation or by immunosuppression.
IT IS A WIDELY ACCEPTED PREMISE in cancer chemotherapy that the response to treatment of clinically evident disease provides a measure of responsiveness of residual disease. This concept, when coupled with the model developed by Skipper and Schabel (cf. Schabel, 1975) that the whole tumour burden, including micrometastases, is reduced progressively by chemotherapy according to first-order kinetics, describes well the responses of some transplanted tumours, and has provided a satisfactory explanation for the treatment protocols which have proved so successful in the cure of a substantial proportion of children with acute lymphoblastic leukaemia (ALL) who require long periods of maintenance treatment after complete remission has been achieved. (Lister et al., 1981 (Canellos et al., 1974) . These findings suggest that clinically evident disease can respond better to antiproliferative chemotherapy than residual disease. This behaviour was shown strikingly in a patient with breast cancer of Dr Trevor Powles (Royal Marsden Hospital) who had a massive local recurrence after surgery, with no metastasis. The recurrent tumour responded completely to chemotherapy, but the patient died of a heart attack 6 months later. At postmortem examination there was no evidence of cancer at the site of the recurrence but there were lung secondaries. At the time of chemotherapy, any lung lesions must have been much smaller than the local recurrence, yet the lung deposits were not, eliminated, whereas the clinically evident recurrence was cured. It is rarely possible to get such decisive postmortem data to illustrate that clinically evident disease can be eradicated by a course of chemotherapy, (o., 1981). mitosis if the interval between irradiation and hepatectomy is less than a week, but if the interval is a month the number of mitoses following partial hepatectomy is as high in the irradiated as in the control liver (Weinbren et al., 1960) , though with a higher incidence of chromosome breaks (Albert, 1958 (Chapuis et al., 1977 ) (see Fig. 2 ). With some populations, there are clear indications of differentiation under these culture conditions to either neutrophils or macrophages, on the basis of morphology, histochemistry and surface markers (Palu' et al., 1979a) . Using these tests, however, there are some populations (Forbes et al., 1981) for which no evidence of differentiation can be detected in the in vitro culture, but none the less there are indications (40) 8 (35) 15a 1'. ALEXANDER the cells in culture (Table II) . The patients whose cells did not differentiate in culture did not fare detectably worse than those whose cells did differentiate. However, it must be borne in mind that the cells when transplanted as xenografts regress even when they do not show obvious differentiation in culture. With a population of AML which did not differentiate significantly in the normal culture medium, Forbes et al. (1981) found that the rate of differentiation was accelerated by adding prostaglandin A (Fig. 3) . This suggests that differentiation of at least some AML cell populations is capable of being modified by physiological factors.
Dormant mnetastasis
The interpretation I have offered for resistance of some subclinical cancer to antiproliferative drugs is similar to one of the mechanisms advanced for tumour dormancy. There are many clinical instances, particularly in cancer of the breast and melanoma, in which tumours locally removed recur locally or as metastases after a long disease-free interval. Tumour dormancy can be studied in experimental U) Ii U, I-. U, 2 z a systems. Fisher & Fisher (1959) showed that a few tumour cells inoculated intraportally remained dormant within the liver until their growth was stimulated by unknown factors associated with hepatic trauma. With oestrogen-dependent tumours, dormancy extending for very long periods can be detected by transplanting the tumours into noirmal recipients, in which no growth occurs, and then admininistering oestrogen, when macroscopic growth sets in. Noble & Hoover (1975) , Eccles & Alexander (1975) and Eccles et al. (1980) found that dormant metastases were common in chemically induced rodent sarcomas and lymphomas which did not metastasize frequently when transplanted to normal syngeneic animals, in which they can be "cured" by surgical removal of the primary implant and its draining node. When such tumours were allowed to grow for a set period before being excised surgically, dormant metastases, seeded from the primary implant before it was excised, were revealed as lung or distant lymph-node metastases after immunosuppression, especially that caused by Cyclosporin A (Eccles et al., 1980) , long after surgery (Fig. 4) . Similarly, cell sus- The normal tissues at high risk to the conventional antimitotic chemotherapy are those of high turnover (i.e. marrow and mucosae of the GI tract) but these are unaffected in GvH disease, which produces its symptoms and can kill by damaging the skin at the dermal-epidermal junction, the liver at the level of the bile-duct epithelium and the gut by processes which do not primarily involve the mucosae. That GvH disease also attacks leukaemia has been known in experimental animals for a long time (cf. Okunewick et al., 1981) but it has only very recently been recognized that it may have a role in preventing recurrence of AMIL in man. The Seattle group (Weiden et al., 1981) have found that recurrence of AML can be greatly reduced if patients in remission are given 10 Gy of total-body irradiation followed by marrow graft. This procedure was initiated on the assumption that the irradiation would eradicate residual AML cells left after intensive chemotherapy, and the marrow graft was given to reverse an otherwise lethal ablation of marrow function. The severity of the ensuing GvH disease varies, and depends on the genetic disparity between patient and marrow donor. On analysing their results (Fig. 5) 
